Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched the HA5® Hydra Collagen Hydrating Foaming Cleanser, expanding its SkinMedica® HA5® Hydra Collagen portfolio. The cleanser features the company's proprietary HA5® Hydra Collagen Complex, combining five forms of hyaluronic acid and vegan hydra collagen.
The product uses 100% naturally derived amino acid-based surfactants and Pea Peptides, differentiating itself from traditional foaming cleansers that often contain harsh sulfates. Clinical studies demonstrate that when used with HA5® Hydra Collagen Replenish + Restore Hydrator, the cleanser instantly boosts skin hydration by 30%. The product is priced at $48 MSRP and is available through SkinMedica.com.
["Clinical studies show 30% instant boost in skin hydration when used with companion product", "Product uses 100% naturally derived amino acid-based surfactants, addressing market demand for natural ingredients", "Expands existing successful HA5® product line with complementary offering"]AbbVie (NYSE:ABBV) has announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. This expansion is part of AbbVie's broader $10 billion U.S. investment commitment over the next decade.
Construction of the new API facility will begin in fall 2025 and is expected to be fully operational by 2027. The expansion will enhance AbbVie's chemical synthesis capabilities for neuroscience, immunology, and oncology medicines, while supporting over 6,000 American jobs across 11 manufacturing sites.
Allergan Aesthetics (NYSE:ABBV) announces the third annual JUVÉDERM® Day on August 20, 2025, featuring exclusive offers for Allē Members. The celebration includes a Buy One Get One (BOGO) promotion where members can purchase a $75 JUVÉDERM® gift card and receive another $75 gift card free.
The company is also launching a $10,000 sweepstakes for Allē Members who receive JUVÉDERM® treatments between September 20-30, 2025. JUVÉDERM®, the #1 chosen hyaluronic acid filler collection in the U.S., offers six unique FDA-approved formulations for 10 specific facial areas. The program includes flexible payment options through Allē Payment Plans powered by Cherry.
Allergan Aesthetics (NYSE:ABBV) has launched its Faces of Natrelle® campaign, featuring nine women sharing their personal experiences with breast augmentation and reconstruction using Natrelle® breast implants. The campaign, selected through a nationwide casting call, includes diverse stories from breast cancer survivors, mothers, and professionals who chose breast procedures for various personal reasons.
The initiative aims to increase transparency and understanding around breast procedures, which remain among the most popular cosmetic and reconstructive surgeries in the U.S. Natrelle® offers 300 options with five profiles and three gel types for customized results. The campaign will be featured across social media channels and digital platforms, showcasing real stories of transformation and empowerment.
AbbVie (NYSE:ABBV) reported strong Q2 2025 financial results with net revenues of $15.423 billion, up 6.6% year-over-year. The company's immunology portfolio led growth with $7.631 billion in revenues, driven by Skyrizi ($4.423B) and Rinvoq ($2.028B). Neuroscience portfolio revenues grew 24.2% to $2.683 billion.
Key highlights include FDA approval for Rinvoq in giant cell arteritis and Emrelis for non-small cell lung cancer. The company raised its 2025 adjusted EPS guidance to $11.88-$12.08 from $11.67-$11.87, despite a $0.55 per share impact from IPR&D expenses.
Q2 adjusted diluted EPS increased 12.1% to $2.97, while GAAP EPS decreased 32.5% to $0.52, impacted by $0.42 per share from IPR&D expenses.
AbbVie (NYSE:ABBV) announced positive topline results from Study 2 of its Phase 3 UP-AA clinical trial evaluating upadacitinib (RINVOQ®) for severe alopecia areata treatment. The trial achieved its primary endpoint with 44.6% and 54.3% of patients treated with upadacitinib 15mg and 30mg respectively achieving ≥80% scalp hair coverage at week 24, compared to 3.4% for placebo.
Key secondary endpoints were also met, with 36.0% and 47.1% of patients reaching ≥90% scalp coverage in the respective dosage groups. The safety profile aligned with approved indications, with treatment-emergent serious adverse events occurring in 1.4% (15mg) and 2.8% (30mg) of patients. Common side effects included acne, nasopharyngitis, and upper respiratory tract infection. Results from Study 1 are expected in Q3 2025.
[ "Strong efficacy with 54.3% of patients achieving ≥80% scalp hair coverage at highest dose", "First pivotal program to achieve complete scalp hair regrowth (SALT=0)", "Successful achievement of both primary and key secondary endpoints", "Generally consistent safety profile with approved indications" ]AbbVie (NYSE:ABBV) has submitted a supplemental New Drug Application (sNDA) to the FDA for a novel combination therapy using VENCLEXTA® (venetoclax) and acalabrutinib to treat previously untreated Chronic Lymphocytic Leukemia (CLL) patients.
The submission is supported by the Phase 3 AMPLIFY trial, which demonstrated statistically significant improvement in progression-free survival compared to standard chemoimmunotherapy. If approved, this would be the first all-oral, fixed-duration combination regimen of these drugs for CLL treatment, offering patients the potential benefit of treatment-free periods.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the 2025 class for The Confidence Project, an initiative led by BOTOX® Cosmetic to support women entrepreneurs. The program includes a Virtual Community Summit, followed by a 12-week intensive "Boostcamp" powered by Hello Alice.
Selected entrepreneurs will receive business development coaching, mentorship, and community support. Following the Boostcamp, participants will compete in a Pitch Lab, where 20 business owners will be selected to receive $20,000 grants each from BOTOX® Cosmetic. The grant recipients will be announced in October 2025.
AbbVie (NYSE: ABBV) has entered into an exclusive licensing agreement with IGI Therapeutics SA for ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, plus tiered, double-digit royalties on net sales.
ISB 2001 was developed using IGI's proprietary BEAT® protein platform and represents a new frontier in immuno-oncology by engaging multiple targets simultaneously.
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition centers on Capstan's lead asset CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy currently in Phase 1 clinical trials for B cell-mediated autoimmune diseases.
CPTX2309 delivers mRNA encoding an anti-CD19 chimeric antigen receptor to CD8-expressing cytotoxic T cells in vivo, offering a novel approach to treating autoimmune conditions. The therapy aims to deplete autoreactive antibody-producing pathogenic memory B cells and achieve immune system reset without requiring lymphodepletion preconditioning or complex ex vivo manufacturing.
The acquisition also includes Capstan's proprietary tLNP platform technology designed for RNA payload delivery. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act requirements.
[ "Acquisition of potential first-in-class therapy CPTX2309 currently in Phase 1 trials", "Technology eliminates need for complex ex vivo manufacturing and lymphodepletion preconditioning", "Platform has potential to treat wide range of autoimmune diseases", "Acquisition includes valuable proprietary tLNP platform technology" ]FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
